SYBX

Companies
NASDAQ
Synlogic Inc.
Health Care
Price Chart
Overview

About SYBX

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Market Cap
$18.5M
Volume
17.3K
Avg. Volume
15.4K
P/E Ratio
-2.4042554
Dividend Yield
0.00%
Employees
56.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.99
Moderate Correlation
Volatility
High (0.67)
Relative to market
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for SYBX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, SYBX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$18.5M
Volume17.3K
P/E Ratio-2.40
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 7, 2025

PortfolioPilot Analysis

Get AI-powered insights on how SYBX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025